Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry.
Redder L, Klausen TW, Vangsted AJ, Gregersen H, Andersen NF, Pedersen RS, Szabo AG, Frederiksen M, Frølund UC, Helleberg C, Nielsen LK, Pedersen PT, Salomo M, Gimsing P, Frederiksen H, Abildgaard N. Redder L, et al. Among authors: andersen nf. Br J Haematol. 2021 Apr;193(1):119-124. doi: 10.1111/bjh.16806. Epub 2020 Jun 9. Br J Haematol. 2021. PMID: 32515050 Free article.
Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma.
Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmström M, Gregersen H, Vogel U, Schwarz P, Jørgensen NR. Vangsted AJ, et al. Among authors: andersen nf. Eur J Haematol. 2014 Aug;93(2):172-4. doi: 10.1111/ejh.12353. Epub 2014 May 17. Eur J Haematol. 2014. PMID: 24766221 No abstract available.
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.
Holmström MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, Klausen TW, Frederiksen M, Kristensen DL, Larsen H, Pedersen PT, Andersen KT, Pedersen RS, Jensen BA, Gregersen H, Vangsted AJ. Holmström MO, et al. Among authors: andersen kt, andersen nf. Am J Hematol. 2015 Apr;90(4):E73-4. doi: 10.1002/ajh.23932. Epub 2015 Feb 2. Am J Hematol. 2015. PMID: 25561348 Free article. No abstract available.
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Østergaard B, Gregersen H, Frølund UC, Andersen NF, Helleberg C, Andersen KT, Pedersen RS, Pedersen P, Abildgaard N, Gimsing P; Danish Myeloma Study Group. Sørrig R, et al. Among authors: andersen kt, andersen nf. Eur J Haematol. 2016 Sep;97(3):303-9. doi: 10.1111/ejh.12728. Epub 2016 Feb 5. Eur J Haematol. 2016. PMID: 26710662
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S. Gimsing P, et al. Among authors: andersen nf. Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29. Bone Marrow Transplant. 2015. PMID: 26121108 Free PMC article. Clinical Trial.
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, Gregersen H, Vogel U. Vangsted AJ, et al. Among authors: andersen nf. Haematologica. 2009 Sep;94(9):1274-81. doi: 10.3324/haematol.2008.004572. Haematologica. 2009. PMID: 19734419 Free PMC article. Clinical Trial.
57 results